金媛媛;庄俊玲;
JIN Yuan-yuan;ZHUANG Jun-ling;Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院血液内科

摘要(Abstract)：

多发性骨髓瘤(multiple myeloma,MM)患者的总生存期(overall survival,OS)在过去20年间从3年延长至8¹0年,这得益于蛋白酶体抑制剂和免疫调节药物等的广泛应用。即使在新药时代,自体造血干细胞移植(autologous stem cell transplantation,ASCT)仍可显著提高移植后反应率,增加微小残留病变阴性率,延长无进展生存期。ASCT对OS的影响在不同研究中结果并不一致,这主要与进展后采用不同治疗方案有关。随着更多新药的出现,ASCT后复发患者会有更多选择。故新药时代,ASCT仍是MM患者诱导治疗后的一线巩固方案。
The overall survival( OS) in patients with multiple myeloma( MM) has been prolonged from3 years to 8-10 years during the past 20 years,which benefits from the broad use of novel agents including proteasome inhibitors and immune modulatory drugs. Even in the era of novel medicines,high-dose melphalan followed by autologous stem cell transplantation( ASCT) is the standard treatment for transplant candidates of newly diagnosed MM. ASCT significantly further improves the post-transplant response rate and the proportion of negative minimal residual disease,as well as leading to better progression-free survival. Nevertheless,the effect of ASCT on OS was not consistent among different clinical trials,which was probably related to different strategies after relapse. As other novel methods including monoclonal antibodies and immune therapies are being developed,more alternatives will be considered. Therefore,ASCT is still the front-line consolidation regimen for transplant candidates with MM.

关键词(KeyWords)： 自体造血干细胞移植;蛋白酶体抑制剂;免疫调节药物;生存期
autologous stem cell transplantation;proteasome inhibitors;immune modulatory drugs;survival

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院创新工程项目(CAMS-2016-I2M-3-025)

作者(Authors): 金媛媛;庄俊玲;
JIN Yuan-yuan;ZHUANG Jun-ling;Department of Hematology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1]Anderson KC.Progress and paradigms in multiple myeloma[J].Clin Cancer Res,2016,22:5419-5427.
• [2]Mc Elwain TJ,Powles RL.High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J].Lancet,1983,2:822-824.
• [3]Attal M,Harousseau JL,Stoppa AM,et al.A prospective,randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.Intergroupe Francais du Myelome[J].N Engl J Med,1996,335:91-97.
• [4]Child JA,Morgan GJ,Davies FE,et al.Medical research council adult leukaemia working party.High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma[J].N Engl J Med,2003,348:1875-1883.
• [5]Martinez-Lopez J,Blade J,Mateos MV,et al.Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J].Blood,2011,118:529-534.
• [6]Attal M,Harousseau JL,Facon T,et al.Single versus double autologous stem-cell transplantation for multiple myeloma[J].N Engl J Med,2003,349:2495-2502.
• [7]BladéJ,Rosi1ol L,Sureda A,et al.High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA[J].Blood,2005,106:3755-3759.
• [8]Roussel M,Lauwers-Cances V,Robillard N,et al.Frontline transplantation program with lenalidomide,bortezomib,and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma:a phase II study by the Intergroupe Francophone du Myélome[J].J Clin Oncol,2014,32:2712-2717.
• [9]Koreth J,Cutler CS,Djulbegovic B,et al.High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J].Biol Blood Marrow Transplan,2007,13:183-196.
• [10]Sonneveld P,Goldschmidt H,Rosi1ol L,et al.Bortezomibbased versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma:a meta-analysis of phase III randomized,controlled trials[J].J Clin Oncol,2013,31:3279-3287.
• [11]Harousseau JL,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase III trial[J].JClin Oncol,2010,28:4621-4629.
• [12]Sonneveld P,Schmidt-Wolf IG,van der Holt B,et al.Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase III HOVON-65/GMMG-HD4 trial[J].J Clin Oncol,2012,30:2946-2955.
• [13]Rosi1ol L,Oriol A,Teruel AI,et al.Superiority of bortezomib,thalidomide,and dexamethasone(VTD)as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J].Blood,2012,120:1589-1596.
• [14]Cavo M,Tacchetti P,Patriarca F,et al.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before,and consolidation therapy after,double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3study[J].Lancet,2010,376:2075-2085.
• [15]Palumbo A,Cavallo F,Gay F,et al.Autologous transplantation and maintenance therapy in multiple myeloma[J].NEngl J Med,2014,371:895-905.
• [16]Richardson PG,Weller E,Lonial S,et al.Lenalidomide,bortezomib,and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma[J].Blood,2010,116:679-686.
• [17]Attal M,Lauwers-Cances V,Hulin C,et al.Lenalidomide,Bortezomib,and Dexamethasone with transplantation for myeloma[J].N Engl J Med,2017,376:1311-1320.
• [18]Attal M,Harousseau JL,Leyvraz S,et al.Maintenance therapy with thalidomide improves survival in patients with multiple myeloma[J].Blood,2006,108:3289-3294.
• [19]Spencer A,Prince HM,Roberts AW,et al.Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J].J Clin Oncol,2009,27:1788-1793.
• [20]Barlogie B,Tricot G,Anaissie E,et al.Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J].N Engl J Med,2006,354:1021-1030.
• [21]Barlogie B,Pineda-Roman M,van Rhee F,et al.Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities[J].Blood,2008,112:3115-3121.
• [22]Lokhorst HM,van der Holt B,Zweegman S,et al.A randomized phase 3 study on the effect of thalidomide combined with adriamycin,dexamethasone,and high-dose melphalan,followed by thalidomide maintenance in patients with multiple myeloma[J].Blood,2010,115:1113-1120.
• [23]Morgan GJ,Gregory WM,Davies FE,et al.The role of maintenance thalidomide therapy in multiple myeloma:MRCMyeloma IX results and meta-analysis[J].Blood,2012,119:7-15.
• [24]Attal M,Lauwers-Cances V,Marit G,et al.Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J].N Engl J Med,2012,366:1782-1791.
• [25]Mc Carthy PL,Owzar K,Hofmeister CC,et al.Lenalidomide after stem-cell transplantation for multiple myeloma[J].NEngl J Med,2012,366:1770-1781.
• [26]Michaelis LC,Saad A,Zhong X,et al.Salvage second hematopoietic cell transplantation in myeloma[J].Biol Blood Marrow Transplant,2013,19:760-766.
• [27]Kumar SK,Lacy MQ,Dispenzieri A,et al.Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma[J].Cancer,2012,118:1585-1592.